AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02552303 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for Nuvigil (armodafinil)
Study NCT00740012 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuous glucose monitoring
Description: Glucoday S (microdialysis system). Continuous glucose monitoring all three nights
Study NCT00740012 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: alarm- clock intervention, patient perform blood glucose self monitoring
Description: Alarm clock intervention at midnight, 2 a.m., 4 a.m. and 6:45 a.m.
Study NCT00740012 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: nurse intervention
Description: Nurse intervention: gently drawing capillary sample (blood glucose)at midnight, 2 a.m., 4 a.m. and 6:45 a.m. .
Study NCT00740012 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Taking the patients pulse
Description: In nights (a) and (b) the doctoral candidate takes the patients pulse 5-7 minutes after the alarm clock or the nurse.
Study NCT00740012 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Venous blood drawing
Description: Venous blood drawing for the determination of epinephrine, norepinephrine, cortisol, glucagon, growth hormone, and prolactin (determined by specific immunoassays at Biocientia laboratories, Jena, Germany) (6-10 minutes after midnight, 2 a.m., 4 a.m. and 6:45 a.m.)in night (a) and (b)
Study NCT00740012 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Other capillary sample
Description: 5-7 minutes after the alarm clock or the nurse the doctoral candidate takes another capillary sample for a laboratory glucose determination (EBIOS, Eppendorf, Hamburg, Germany) analyzer.
Study NCT01325454 — intervention group
Intervention type: DEVICE
Intervention: pleural pigtail drainage
Description: With the guidance of chest US, 50 ml of pleural fluid was collected using a standard thoracentesis technique immediately or within 24 hr after hospitalization. When pleural effusion was multi-loculated, the fluid was aspirated from the largest loculus. Routine analyses of pleural fluid for total leukocytes, cell differentials of leukocytes, pH value, and levels of protein, glucose and LDH were performed in addition to cytological and microbiologic examination of pleural fluid.The rest of pleural fluid samples were mixed with 3.8 % sodium citrate in a 9:1 ratio of pleural fluid to citrate. The sodium citrate-mixed pleural fluid specimens were immersed in ice immediately and then centrifuged at 2,500 g for 10 minutes. The cell-free supernatants of pleural fluid were frozen at -70℃ immediately after centrifuge for later measurements. The commercially available enzyme-linked immunosorbent assay kits were used to measure the effusion levels of VEGF, IL-8 , tPA and PAI-1.
Study NCT04042051 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Copanlisib
Description: Copanlisib is supplied as lyophilized preparation in a 6mL injection vial. The total amount of copanlisib per vial is 60mg. The solution for IV infusions is obtained after reconstitution with normal saline solution. Copanlisib will be administered on Days 1 (and 8 and 15 \[according to the dose escalation scheme\]) of each 21-day cycle. Copanlisib will be administered first over 60 minutes followed by the infusion of trastuzumab emtansine.
Study NCT04042051 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Trastuzumab emtansine
Description: Trastuzumab emtansine 3.6mg/kg IV infusion on Day 1 of each 21-day treatment cycle.
Study NCT01538979 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BM32
Description: Subcutaneous injection of 20 micrograms of each of the protein components of BM32 adsorbed on 0.6 mg of aluminum hydroxide every 4 weeks for a total of 3 injections before each pollen season and one boost injection after pollen season
Study NCT01538979 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BM32
Description: Subcutaneous injection of 40 micrograms of each of the protein components of BM32 adsorbed on 1.2 mg of aluminum hydroxide every 4 weeks for a total of 3 injections before each pollen season and one boost injection after pollen season
Study NCT01538979 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection of 1.2 mg of aluminum hydroxide suspension every four weeks before each pollen season and one injection after pollen season for a total of 7 injections
Study NCT04164017 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EUS-guided FNB with Syringe Suction
Description: For each case, FNB will be performed using two punctures: one with 20mL syringe suction and another without aspiration. The order in which they will be performed will be known only by the performing physician and the nursing team at the time that FNB is proposed. This information will be concealed from the pathologist responsible for sample analysis.
Study NCT04164017 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EUS-guided FNB without Syringe Suction
Description: For each case, FNB will be performed using two punctures: one with 20mL syringe suction and another without aspiration. The order in which they will be performed will be known only by the performing physician and the nursing team at the time that FNB is proposed. This information will be concealed from the pathologist responsible for sample analysis.
Study NCT00561158 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eat Well Live Well Nutrition Program
Description: 12 sessions (6 group and 6 individual)over a period of 3 months with a 3 month follow-up period. The group sessions involve active learning exercises crucial to learning and utilizing nutrition information.~The group sessions included are:~* Rate Your Plate: determining high fat foods~* Label Reading: reading food labels~* Comparison Shopping: using unit pricing labels maximize nutritional value on a limited income~* Recipe Modification: preparing old recipes in new ways to reduce fat~* Eating Out: order healthier fast foods~* Coping with High Risk Situations: coping with situations in which these new habits may be threatened~Six individual sessions will introduce participants to low fat eating patterns or ways to lower fat in their diet, including:~* Substituting fat-modified foods for high fat foods~* Avoiding fat as a seasoning or flavoring~* Avoiding fried foods~* Modifying meat~* Replacing high fat foods with fruits, vegetables, grains and breads
Study NCT03673085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CN128
Description: CN128
Study NCT03673085 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The tablets without CN128
Study NCT05175222 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Laser therapy
Description: Patients receive laser therapy in 7 points in oral cavity every day from the first day of conditioning chemotherapy till the second day post HSCT. Each point is irradiated for 1 minute.
Study NCT03571412 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive Transcranial Magnetic Stimulation
Description: Subject will receive 5Hz LDLPFC or 5Hz DMPFC rTMS
Study NCT01146522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCQ908
Study NCT01146522 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01808534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: palifosfamide
Description: Given IV
Study NCT02958696 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HTL0018318
Description: Two single doses of active drug (low, mid or high dose either as aqueous solution or capsule) separated by a washout of at least 12 days.
Study NCT00613886 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Programmable Shunt Insertion (Codman, Medtronic)
Description: Medical Device - Shunt insertion surgery of adjustable valve and laparoscopic assistance for placement of peritoneal catheter. Patient will be brought to operating room suite where general anesthesia is induced. Patient will be placed with a small roll on shoulder, supine, on the operating room table. Patient's head will be turned with the parietal area uppermost in the field. Patient will be prepared and draped in the usual sterile fashion. Site prep includes parietooccipital area, side of neck, chest, and entire abdomen. Ventricular catheter placed and then attached to shunt valve. Catheter is then fitted over grooved blue burr hole guide. Excess catheter pulled down to pull valve into pocket on the skull. Sterile dressings applied.
Study NCT00613886 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assessments in physical therapy, occupational therapy, and speech therapy
Description: Follow-up testing to be administered by trained Physician Assistant in the outpatient setting on an approximately monthly basis: 10m walk, timed up-and-go, Mini-Mental Status Exam, 9-hole Grooved Pegboard, Motor Visual Perception Test (MVPT), Modified Rankin Score (MRS)
Study NCT03183258 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sentinel skin flap
Description: Donor-derived vascularised composite allograft (sentinel skin flap)
Study NCT03990415 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise is a behavioral intervention, the primary aim of this investigation is to elucidate if strength training is a more effective exercise intervention than walking for the improvement of balance in older adults.
Study NCT03990415 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Exercise is a behavioral intervention, the primary aim of this investigation is to elucidate if strength training is a more effective exercise intervention than walking for the improvement of balance in older adults.
Study NCT02110537 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Active Acupuncture
Description: Active acupuncture treatment group consists of electroacupuncture (EA) and intradermal acupuncture (IDA). For EA treatment, unilateral PC5, PC6, ST36, and ST37 are chosen. Disposable, sterile needles and low frequency electrical stimulator (ES-160, ITO, Japan) are used. Each needle is inserted to the depth of 2 ± 0.5 cm with a 90 degree angle. Thereafter, needles are connected with the pole and electrical stimulation is applied with 2Hz, continuous wave current for 20 minutes. For IDA treatment, bilateral HT7 and TF4 are selected. Disposable, sterile, sticker-type needles (0.18 mm x 1.3 mm x 1.5mm) are used. Attached needles are maintained as long as possible.
Study NCT02110537 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture
Description: For sham intervention, nonacupuncture points are used. As with active treatment group, two types of acupuncture, sham EA and sham IDA, compose the sham intervention. Electrical acupuncture is connected but electrical stimulation is not given to sham acupuncture group.
Study NCT02110537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flecainide
Description: Both groups commonly take antiarrhythmic medication (flecainide 75 mg twice daily) during study period. Flecainide administration is initiated 2 weeks before electrical cardioversion and maintain during follow up period.
Study NCT02110537 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: flecainide
Description: Both groups commonly take antiarrhythmic medication (flecainide 75 mg twice daily) during study period. Flecainide administration is initiated 2 weeks before electrical cardioversion and maintain during follow up period.
Study NCT04679922 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Soft Tissue Enhancement around dental implant
Description: Sixteen sites that are indicated for peri-implant mucosal augmentation at the time of implant placement will be selected. Sixteen sites that were met the subsequent inclusion criteria were eligible to contribute in our study were classified randomly by the sealed envelope technique into two treatment groups, 8 sites in each group. Group I (Control Group): Autogenous SCTGs harvested from the palate +dental implants \*. Group II (Experimental Group): FLA \*\*+dental implants. The allocation was withheld from the surgeon (M.H.) until just before the surgical appointment. The clinical examiner (M.S.) was masked to the treatment group for the extent of the study.Three months after implantation, the sites were located, and the thickness of the mucosa will be evaluated using the customized stent. The operculectomy will be performed following the method of Flatebo et al.,22 collecting biopsy specimens of almost constant quality and evaluating clinical thickness without mucosal distortions
Study NCT04679922 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Soft Tissue Enhancement around dental implant
Description: Sixteen sites that are indicated for peri-implant mucosal augmentation at the time of implant placement will be selected. Sixteen sites that were met the subsequent inclusion criteria were eligible to contribute in our study were classified randomly by the sealed envelope technique into two treatment groups, 8 sites in each group. Group I (Control Group): Autogenous SCTGs harvested from the palate +dental implants \*. Group II (Experimental Group): FLA \*\*+dental implants. The allocation was withheld from the surgeon (M.H.) until just before the surgical appointment. The clinical examiner (M.S.) was masked to the treatment group for the extent of the study.Three months after implantation, the sites were located, and the thickness of the mucosa will be evaluated using the customized stent. The operculectomy will be performed following the method of Flatebo et al.,22 collecting biopsy specimens of almost constant quality and evaluating clinical thickness without mucosal distortions
Study NCT00705250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bendamustine hcl
Description: Patients will receive bendamustine 120mg/m\^2, administered as a 30-minute infusion, for two consecutive days. Cycles will be repeated every four weeks and a total of 6 cycles will be planned. Patients will receive pegfilgrastim with each cycle. Treatment will be delayed until the absolute neutrophil count is > 1000/ul and the platelet count is > 75,000/ul.
Study NCT00774644 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin 500mg
Study NCT02931968 — intervention group
Intervention type: DEVICE
Intervention: Monolithic zirconia prosthesis
Description: Edentulous arch subjects treated with a monolithic zirconia implant supported fixed dental prosthesis.
Study NCT00948129 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00948129 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01438034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: kisspeptin 112-121
Description: 0.24 nmol/kg
Study NCT01438034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH
Description: 75 ng/kg
Study NCT04316936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omidria
Description: phenylephrine 1% and ketorolac 0.3% intraocular solution
Study NCT04316936 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omidria
Description: phenylephrine 1% and ketorolac 0.3% intraocular solution
Study NCT04316936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextenza (dexamethasone ophthalmic insert) 0.4mg
Description: intracanalicular dexamethasone insert
Study NCT04316936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexycu, 9% Intraocular Suspension
Description: dexamethasone intraocular suspension
Study NCT04316936 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone Acetate 1%
Description: standard postoperative ophthalmic drop regimen
Study NCT02182479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berodual® via Respimat®, high dose
Study NCT02182479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berodual® via Respimat®, low dose
Study NCT02182479 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Berodual® via MDI, high dose
Study NCT02182479 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Respimat®
Study NCT02182479 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo MDI
Study NCT00990600 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: reduced number of pills
Description: Switch to a fixed dose combination one pill/daily HAART
Study NCT01096472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS41003
Description: Once daily
Study NCT01096472 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LAS189961
Description: Once daily
Study NCT01096472 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LAS189962
Description: Once daily
Study NCT00862043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil Citrate
Description: 40 mg t.i.d.
Study NCT00862043 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo t.i.d.
Study NCT03614663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZYN002 - Cannabidiol Transdermal Gel
Description: Pharmaceutically manufactured. Cannabidiol formulated as a clear gel (transdermal delivery)
Study NCT03614663 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Transdermal Gel
Description: Placebo formulated as a clear gel (transdermal delivery)
Study NCT04039906 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Removal of needle with using ANDYs
Description: 1. ANDY will be provided to medical staffs to be use in removal needles from syringes during 7 days~2. Record the time required for the needle removal procedure by photographing the needle removal procedure during 24 hours/7 days.~   Identify the number of syringes processed by ANDY.~3. After 3rd week, do survey and interview 15 people selected by the convenient sample method. By interviewing, collect information of overall experience after using automated needle processing system, how long their hospital working experience is, and other information or systems the interviewees felt those are necessary.
Study NCT01532648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide MMX®
Description: Oral tablet taken daily in the morning after breakfast.
Study NCT01532648 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching budesonide MMX placebo oral tablet taken daily in the morning after breakfast.
Study NCT01532648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-ASA
Description: Acceptable oral 5-ASA medications to be received during the study include:~* Asacol®, Asacol® HD, Lialda®, Pentasa® (generic: mesalamine), minimum daily dose ≥2.4 grams (g)~* Azulfidine® (generic: sulfasalazine), minimum daily dose ≥4.0 g~* Dipentum® (generic: olsalazine), minimum daily dose ≥2.0 g~* Colazal®, Colazide® (generic: balsalazide), minimum daily dose ≥6.75 g
Study NCT01532648 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5-ASA
Description: Acceptable oral 5-ASA medications to be received during the study include:~* Asacol®, Asacol® HD, Lialda®, Pentasa® (generic: mesalamine), minimum daily dose ≥2.4 grams (g)~* Azulfidine® (generic: sulfasalazine), minimum daily dose ≥4.0 g~* Dipentum® (generic: olsalazine), minimum daily dose ≥2.0 g~* Colazal®, Colazide® (generic: balsalazide), minimum daily dose ≥6.75 g
Study NCT03311360 — intervention group
Intervention type: DEVICE
Intervention: drug-coated balloon
Description: Orchid and Dahlia DCB
Study NCT03311360 — intervention group
Intervention type: DEVICE
Intervention: bare metal stent
Description: any type of bare metal stent
Study NCT01750684 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AC105
Study NCT01750684 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00575016 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Normal saline (Placebo); botulinum toxin Type A (200U)
Description: Placebo injection on Day 1 and botulinum toxin Type A injection 200 U > Week 12; injection into the detrusor
Study NCT00575016 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin Type A (50U); botulinum toxin Type A (200U)
Description: botulinum toxin Type A 50 U on Day 1 followed by botulinum toxin Type A 200 U > 12 weeks; injections into the detrusor
Study NCT00575016 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin Type A (100U); botulinum toxin Type A (200U)
Description: botulinum toxin Type A 100 U on Day 1 followed by botulinum toxin Type A 200 U > 12 weeks; injections into the detrusor
Study NCT00575016 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin Type A (200U)
Description: botulinum toxin Type A 200 U on Day 1 followed by botulinum toxin Type A 200 U > 12 weeks; injections into the detrusor
Study NCT01970410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: teriflunomide
Description: 14 mg oral teriflunomide daily
Study NCT02568215 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC01
Description: Administered by IV infusion; total dose will vary based on participant's weight
Study NCT02568215 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for VRC01
Description: Sodium Chloride for Injection USP, 0.9%; administered by IV infusion
Study NCT02148705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NexoBrid
Study NCT02148705 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care (SOC)
Study NCT02148705 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gel Vehicle